SANTA ANA, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, announced today that its management team is doing so will be present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022 in New York City. See below for details:
Baird Global Health Conference
Format: company presentation
Date: Wednesday 14 September 2022
Time: 2:35 p.m. ET
Location: New York, NY
Registration: conference link
NKGen Biotech will also hold one-on-one meetings with investors. To schedule an appointment, please contact your Baird representative.
About NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging our proprietary cell expansion and activation technology and state-of-the-art cell manufacturing expertise, we are able to infinitely expand natural killer cells while significantly enhancing the cytotoxicity of our peripheral blood-derived products. NKGen Biotech’s lead product candidate, SNK01, is currently in clinical trials for the treatment of advanced refractory solid tumors both as monotherapy and in combination with other agents, including checkpoint inhibitors and cell engagers. NKGen Biotech is committed to the vision of executing our clinical strategies to commercialize our NK cell therapies to help save and sustain the lives of patients worldwide. The Company and its commercially licensed cGMP facility are headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
949-396-6830
dchua@nkgenbiotech.com
A photo accompanying this announcement is available at
